Morgane Mannes, , , Dora Mugoli Chigoho, , , Charlotte Martin, , , Thomas Barlow, , , Tine Hectors, , , Tom Govaerts, , , Pieterjan Kayaert, , , Kirsten De Ridder, , , Carole Delachaume, , , Béatrice Vayssière, , , Martin Andrews*, , , Sophie Hernot*, , and , Steven Ballet*,
{"title":"Targeted Delivery of Oligonucleotide–Peptide Conjugates for Enhanced Kidney-Specific Therapy","authors":"Morgane Mannes, , , Dora Mugoli Chigoho, , , Charlotte Martin, , , Thomas Barlow, , , Tine Hectors, , , Tom Govaerts, , , Pieterjan Kayaert, , , Kirsten De Ridder, , , Carole Delachaume, , , Béatrice Vayssière, , , Martin Andrews*, , , Sophie Hernot*, , and , Steven Ballet*, ","doi":"10.1021/acs.jmedchem.5c01893","DOIUrl":null,"url":null,"abstract":"<p >Targeted drug delivery has emerged as a crucial strategy to enhance efficacy and minimize side effects from off-target interactions, a particularly relevant approach for kidney diseases, where many treatments suffer from poor targeting efficiency. In this study, we benchmarked a series of peptides previously identified for their kidney-targeting potential, utilizing them as targeting moieties for an oligonucleotide aimed at repressing HIF-1α expression in renal tubular cells. The peptides were synthesized, radiolabeled, and evaluated for their biodistribution profiles in mice. The best-performing peptide was conjugated to the oligonucleotide of interest, leveraging its kidney-targeting properties to optimize the delivery. We demonstrated that conjugation of the oligonucleotide to a kidney-targeting peptide preserved its repressing HIF-1α activity, while increasing accumulation 10-fold in the kidneys. The results from this study offer valuable insights into the potential of kidney-targeting peptides as a novel strategy to improve the efficacy and safety of therapies for kidney diseases.</p>","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"68 18","pages":"19584–19597"},"PeriodicalIF":6.8000,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c01893","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
Targeted drug delivery has emerged as a crucial strategy to enhance efficacy and minimize side effects from off-target interactions, a particularly relevant approach for kidney diseases, where many treatments suffer from poor targeting efficiency. In this study, we benchmarked a series of peptides previously identified for their kidney-targeting potential, utilizing them as targeting moieties for an oligonucleotide aimed at repressing HIF-1α expression in renal tubular cells. The peptides were synthesized, radiolabeled, and evaluated for their biodistribution profiles in mice. The best-performing peptide was conjugated to the oligonucleotide of interest, leveraging its kidney-targeting properties to optimize the delivery. We demonstrated that conjugation of the oligonucleotide to a kidney-targeting peptide preserved its repressing HIF-1α activity, while increasing accumulation 10-fold in the kidneys. The results from this study offer valuable insights into the potential of kidney-targeting peptides as a novel strategy to improve the efficacy and safety of therapies for kidney diseases.
期刊介绍:
The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents.
The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.